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ABSTRACT
Introduction: Aortic stenosis (AS) is the commonest
valve disorder in the developed world requiring
surgery. Surgery in patients with severe asymptomatic
AS remains controversial. Exercise testing can identify
asymptomatic patients at increased risk of death and
symptom development, but with limited specificity,
especially in older adults. Cardiac MRI (CMR),
including myocardial perfusion reserve (MPR) may be
a novel imaging biomarker in AS.
Aims: (1) To improve risk stratification in
asymptomatic patients with AS and (2) to determine
whether MPR is a better predictor of outcome than
exercise testing and brain natriuretic peptide (BNP).
Method/design: Multicentre, prospective
observational study in the UK, comparing MPR with
exercise testing and BNP (with blinded CMR analysis)
for predicting outcome.
Population: 170 asymptomatic patients with
moderate-to-severe AS, who would be considered for
aortic valve replacement (AVR).
Primary outcome: Composite of: typical symptoms
necessitating referral for AVR and major adverse
cardiovascular events. Follow-up: 12–30 months
(minimum 12 months).
Primary hypothesis: MPR will be a better predictor
of outcome than exercise testing and BNP.
Ethics/dissemination: The study has full ethical
approval and is actively recruiting patients. Data
collection will be completed in November 2014 and the
study results will be submitted for publication within
6 months of completion.
ClinicalTrials.gov identifier: NCT01658345.
INTRODUCTION
Aortic stenosis (AS) is the commonest valve
lesion requiring surgery in the developed
world.
1 European registry data indicate that
as few as 30% of potentially eligible patients
are referred for surgery.
2 As the population
in developed countries continues to age, it is
predicted that the prevalence of AS will
double in the next 20 years.
3
The development of symptoms in AS
heralds a malignant phase of the condition
and prompt aortic valve replacement (AVR)
results in a clear reduction in mortality.
4
Surgery in this situation is universally
regarded as a class I indication despite the
absence of randomised controlled trials.
56
In contrast, management of patients with
severe AS in the absence of symptoms
Strengths and limitations of this study
▪ Study design: blinded imaging with core lab ana-
lysis (cardiac MR (CMR) and exercise testing) to
reduce referral bias, inclusion only of patients
who would consider surgery, multicentre, data
collection/analysis by independent clinical trials
unit.
▪ Comprehensive phenotyping of participants.
▪ Management and oversight: independent chair
and members of steering committee, independ-
ent event adjudication.
▪ Harder primary endpoint: asymptomatic patients
referred for aortic valve replacement not
included.
▪ Registration with National Health Service
Information services to minimise loss to
follow-up and acquire long-term data.
▪ Coronary disease not excluded by angiography.
▪ CMR not widely available in all secondary care
settings.
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Open Access Protocolremains controversial and continues to provoke debate,
with divergent clinical practice.
78It is generally agreed
that the ideal timing of surgical intervention is immedi-
ately before a patient develops symptoms. Such a strat-
egy, if successfully implemented, would minimise the
risk of sudden death during the long latent (asymptom-
atic) period and minimise the number of patients sent
for surgery who may never have developed symptoms
related to AS.
Risk stratification in asymptomatic patients with
moderate-to-severe AS
Many researchers have therefore sought clinical markers
in asymptomatic patients with AS, that reliably identify
those who will need AVR. The current body of evidence
in asymptomatic AS consists mainly of observational
studies (table 1), which have identiﬁed a number of risk
factors for developing symptoms or death.
89These
include (1) echocardiographic markers: aortic valve cal-
ciﬁcation, rapid increase in pressure gradient,
10 very
high aortic valve velocities
11 12; (2) an abnormal
response or symptoms on exercise testing
13–15 and (3)
abnormal biomarkers, especially brain natriuretic pep-
tides (BNP).
16 It should be noted, however, that echocar-
diographic measures of AS severity are a poor
discriminator between those who go on to develop symp-
toms and those that do not, compared with other
parameters.
13 17
Limitations of current research in asymptomatic AS
The limitations of these research studies have been high-
lighted in a recent editorial.
9 These include a degree of
selection bias due to non-randomisation, unblinded
investigations inﬂuencing management decisions and
patients who subsequently refuse surgery and patients
undergoing AVR while asymptomatic being included in
the primary outcome.
Exercise testing to risk stratify in AS
Of the prognostic markers studied to date, most atten-
tion has focused on exercise testing.
13–15 A recent
meta-analysis of stress testing in 491 asymptomatic
patients with severe AS demonstrated that there was no
sudden death in those with a normal test, which was also
associated with a low risk of subsequent events.
18
However, the speciﬁcity of a positive test is low for pre-
dicting outcome. Das et al
15 showed the positive predict-
ive value of exercise symptoms to be only 57% and even
lower in the large and important group of patients
>70 years of age. It does seem likely that the mechanisms
limiting exercise capacity will closely be related to those
that cause symptoms. However, no trial to date has
assessed whether early AVR can improve outcome in
asymptomatic patients with a positive exercise test (or
for any other risk factor). For this reason the ACC/AHA
guidelines grade exercise-induced symptoms as a class
IIB indication (can be considered but weight of
evidence does not support intervention) for AVR.
19
Exercise testing has not been widely implemented in
clinical practice.
2
Importance of left ventricular remodelling in AS
The hypertrophic response to pressure overload in
severe AS is extremely variable.
20 21 When left ventricu-
lar hypertrophy (LVH) does occur, it is associated with a
number of detrimental pathophysiological sequelae:
reduction in myocardial strain,
22 development of myo-
cardial ﬁbrosis
23 and diastolic dysfunction. These
changes are also associated with microvascular dysfunc-
tion.
24 Patients with AS with high left ventricular mass
index (LVMI) are more likely to develop heart failure,
suggesting that adverse ventricular remodelling is pro-
motive of LV systolic dysfunction.
21 Inappropriately high
LVMI has also been identiﬁed as an adverse prognostic
marker in patients with severe asymptomatic AS.
20
Following AVR there is regression of LVH which has
been associated with improvement in myocardial
strain,
22 myocardial perfusion reserve (MPR)
25 and exer-
cise capacity,
26 but not in all studies.
27 However, there
are concerns that LVH regression is incomplete and that
myocardial ﬁbrosis may be irreversible leading to persist-
ent diastolic dysfunction and increased long-term
mortality.
28
Cardiac MR in AS
Focal myocardial ﬁbrosis can be detected non-invasively
by late gadolinium enhancement (LGE) in 27–62% of
patients with AS.
29 30 The extent of LGE correlates well
with, although underestimates the extent of interstitial
ﬁbrosis on myocardial biopsy
29 31 and increases with
LVH.
29 30 LGE in patients with severe AS is associated
with limited improvement in symptoms, LV function and
higher medium-term mortality after AVR.
29 31
Cardiac MR (CMR) myocardial tissue tagging can also
demonstrate alterations in strain and strain rates, and is
considered the gold standard technique for the assess-
ment of function.
32 In AS there is an increase in the
normal wringing action (torsion) of the LV, which
improves after AVR.
33 The rate of untwisting in AS is
reduced which may reduce diastolic ﬁlling and MPR by
loss of ‘suction’ action.
The importance of CMR detected LVH, LGE and
MPR in predicting objectively measured maximal
aerobic exercise capacity (peak oxygen consumption
(VO2)) in 46 patients with severe isolated AS prior to
AVR has been studied.
34 On stepwise regression analysis,
MPR was the only independent predictor of sex and age-
corrected peak VO2, β=0.457, p=0.001. MPR also signiﬁ-
cantly decreased with increasing New York Heart
Association (NYHA) Class (p=0.001). Newer CMR
methods utilising T1 mapping also offer the possibility
of quantifying diffuse myocardial ﬁbrosis not detected
by the LGE technique.
26 This has also been shown to be
associated with exercise capacity and NYHA class in
patients with severe AS prior to AVR.
26 Diffuse ﬁbrosis
may be an important determinant of MPR
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Open AccessTable 1 Prospective studies assessing risk stratification in moderate-to-severe asymptomatic AS
Author N Severity CAD Outcome
Follow-up:
months AVR
Total/cardiac
deaths SCD Outcome predictor
Rosenhek et al
10 128 Severe (>4 m/s) Not
exclude
Death, AVR 22±18 59 of 106
(56%)
8
6 cardiac
1 (0.9%) Calcification, rapid
progression
Amato et al
13 66 Severe (AVA <1 cm
2) Excluded
(angio)
Death, symptoms 15±12 ?34 4 4 (6.1%) AVA <0.7 cm
2, positive
ETT
Lancellotti et al
14 69 Severe (AVA <1 cm
2) Not
excluded
Symptoms, death,
AVR
15±7 12 (17%) 3 cardiac + 1
death post-AVR
2 (2.9%)
SCD
Exercise mean PG
+ve ETT, AVA
<0.75 cm
2
Das et al
15 125 Moderate-to–severe
(AVA <1.4 cm
2),
Not
excluded
Symptoms, death 12 36 (29%)
symptoms?
AVR
No deaths No SCD Exercise symptoms
Monin et al
40 104 Moderate-to-severe:
>3 m/s AVA <1.5 cm
RWMA
exclude
Indication for AVR,
death
24 58 AVR 4 deaths (1
post-AVR)
Female sex, BNP,
peak velocity
Rosenhek et al
12 116 Very severe >5 m/s Not
excluded
Indication for AVR,
death
41 (median) 79 AVR, 10
refused AVR
17 deaths
9 no surgery
8 post-AVR
1 SCD Peak AV >5.5 m/s,
diabetes, cholesterol
Kang et al
11 197 Very severe >4.5 m/s or
AVA <0.75 cm
2
History or
RWMA
Death 42 AVR
58 medical
148
102 early,
46 (of 95)
medical
3 (0 cardiac)
early, 28 (12
cardiac) medical
9 (10%)
medical
0 early
Peak AV >5 m/s
Cioffi et al
20 209 Severe (AVA<1 cm
2 or
mean PG>40 mm Hg
History Death, AVR, MI,
HF hospitalisation
22±13 72 20 (16 cardiac) 2 SCD Inappropriate high
LVMI, peak velocity,
calcification
Source: Adapted from ref. 9-reproduced with permission.
Angio, coronary angiography; AS, aortic stenosis; AV, aortic valve velocity; AVA, aortic valve area; AVR, aortic valve replacement; BNP, brain natriuretic peptide; CAD, coronary artery disease;
ETT, exercise tolerance test; HF, heart failure; LVMI, left ventricular mass index; MI, myocardial infarction; PG, pressure gradient; RWMA, regional wall motion abnormalities; SCD, sudden
cardiac death.
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spreoperatively. However, early after AVR there is no
signiﬁcant change in diffuse ﬁbrosis
26 28 but MPR does
increase
25 (reﬂecting changes in pressure overload and
reverse LV remodelling
34).
MPR is an attractive biomarker in AS since it is
dependent on a combination of factors that include:
valve severity and measures of LV remodelling/ﬁbrosis
and perfusion time. The primary aim of the PRIMID AS
study is to assess whether MPR (and other CMR mea-
sures) can improve risk stratiﬁcation in asymptomatic
patients with moderate-to-severe AS, by comparing them
to the best studied prognostic indicators: exercise testing
and NT-proBNP.
STUDY DESIGN
This is a multicentre, prospective observational study
with blinded analysis of CMR data. The study has been
registered on ClinicalTrials.gov (NCT01658345).
Aims of the study
▸ To improve risk stratiﬁcation in asymptomatic patients
with AS.
▸ To determine whether MPR is a better predictor of
outcome than exercise testing and NT-proBNP.
▸ To establish the determinants of MPR in asymptom-
atic AS.
Two substudies will:
▸ Assess the reproducibility of MPR measurement in
AS;
▸ Assess the rate of progression in LV remodelling at
1 year in asymptomatic AS.
Primary hypothesis
MPR will be a better predictor of adverse outcome than
exercise testing in asymptomatic patients with
moderate-to-severe AS.
Inclusion and exclusion criteria
These are shown in table 2.
In addition, 20 asymptomatic controls without known
cardiac disease will undergo baseline assessment to allow
determination of age and sex-matched normal ranges
for MPR, diffuse myocardial ﬁbrosis and exercise
capacity.
Primary outcome measures
Composite of typical AS symptoms necessitating referral
for AVR, cardiovascular death and major adverse cardio-
vascular events (MACE; hospitalisation with any of heart
failure, chest pain, syncope, arrhythmia or stroke) at
12 months (time to ﬁrst event). Asymptomatic patients
having AVR for other reasons (valve progression, positive
exercise test) will be excluded from primary endpoint
analysis.
Secondary outcome measures
1. Composite of AVR (for any reason) and MACE at
12 months (ﬁrst event).
2. Composite of AVR and MACE during follow-up (ﬁrst
event).
3. Determinants of exercise capacity (age and sex cor-
rected peak VO2) in AS.
4. Determinants of MPR in AS.
5. Predictors of symptom development in AS.
6. Predictors of progression of diffuse ﬁbrosis and LV
remodelling in AS at 12 months.
7. Predictors of progression in microvascular dysfunc-
tion (reduced MPR) in AS at 12 months.
8. Reproducibility of MPR measurement in AS
(substudy).
Recruitment and data collection
Patients will be recruited from a number of regional hos-
pitals, with testing performed at one of ﬁve tertiary
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Moderate-to-severe AS (≥2 of: AVA <1.5 cm
2, peak pressure gradient
>36 mm Hg, mean PG >25 mm Hg)
History of CABG or recent MI within 6 months
Asymptomatic Previous valve surgery
Age >18 and <85 years Severe valve disease other than AS
Prepared to undergo AVR if symptoms develop Persistent atrial fibrillation or flutter
Ability to perform bicycle exercise test Severe asthma
History of heart failure
Severe renal impairment eGFR <30 mL/min
Planned AVR
EF <40%
Any absolute contraindication to CMR
Contraindication to adenosine
Other medical condition that limits life
expectancy or precludes AVR
Pregnancy
AS, aortic stenosis; AVA, aortic valve area; AVR, aortic valve replacement; CABG, coronary artery bypass grafting; CMR, cardiac MR; EF,
extraction fraction; eGFR, epidermal growth factor receptor; MI, myocardial infarction.
4 Singh A, Ford I, Greenwood JP, et al. BMJ Open 2013;3:e004348. doi:10.1136/bmjopen-2013-004348
Open Accesscardiac centres in the UK with expertise in the manage-
ment of AS and in CMR (Leicester, Leeds, Glasgow,
Dundee and Aberdeen; see ﬁgure 1). Patients will be
identiﬁed from cardiology clinics, echocardiography and
MRI reports. Suitable patients will be approached in out-
patient clinics by a member of the clinical team and
given a patient information sheet (PIS) if interested.
Those who are not due in clinic in the near future will
be posted a PIS with a reply form and stamped
addressed envelope. An electronic case report form
(e-CRF) will be used to collect study data, which has
been developed by the Robertson Centre for
Biostatistics, University of Glasgow. Access to the e-CRF
will be restricted, with only authorised personnel able to
make entries or amendments to patients’ data.
Baseline assessment
Written, informed-consent will be taken from all
patients. Heart rate and blood pressure (BP) will be
recorded and a resting ECG will be performed.
Venepuncture
A blood sample for clinical blood tests, including haem-
atocrit for calculation of myocardial extracellular volume
(ECV), will be drawn. An additional 20 mL of venous
blood will be collected for biomarkers. These samples
will be immediately transferred on ice to a centrifuge,
where they will be centrifuged at 2000 rpm, for 20 min,
at 4°C. Once separated, the plasma will be pipetted into
cryotubes in aliquots and stored in a cryobox in an elec-
tronically monitored freezer at –80°C, for analysis at the
end of the study.
Biobanking
With additional consent, a blood sample will be drawn
and banked for prospective research studies. All tissue
will be collected, stored and disposed of in accordance
with the Codes of Practice as laid out by the Human
Tissue Authority.
Echocardiography
This will be undertaken according to the American
Society of Echocardiography recommendations to deter-
mine AS severity and grade diastolic dysfunction.
35 At
peak exercise, maximal peak and mean aortic valve vel-
ocity will be measured, allowing calculation of valve
compliance.
36
Cardiopulmonary exercise test
A symptom-limited maximal cardiopulmonary exercise
test will be performed on a bicycle ergometer with work-
load increasing at 1 min intervals. Workload increments
will be based on patient age, gender, height and
weight.
37 The test will be physician supervised and BP
will be recorded at 2 min intervals. Indications for
medical termination will be as previously published.
36
Prior to the test initiation patients will be read the fol-
lowing statement: ‘Breathlessness is laboured or difﬁcult
breathing characterised by air hunger and an uncom-
fortable awareness of one’s own breathing.’ The test will
be considered symptomatically positive if the patient
stops prematurely due to limiting breathlessness, chest
tightness or dizziness at <80% of predicted workload.
Results of the cardiopulmonary exercise test will not be
reported unless the responsible cardiologist would have
performed an exercise test for clinical purposes.
Cardiac MR
Patients will be imaged on 3 T CMR platforms because
of the better signal intensity and limits of agreement of
myocardial blood ﬂow with microspheres and better tag
persistence compared to 1.5 T, with similar LV function
analysis. A comprehensive adenosine stress (140 µg/kg/
min for 3 min) and rest perfusion study will be under-
taken (ﬁgure 2), to determine: (1) LV mass and
volumes/ejection fraction; (2) rest and stress myocardial
blood ﬂow and MPR; (3) LGE for focal ﬁbrosis; (4) pre-
contrast and postcontrast T1 mapping at a mid-
ventricular level and (5) Tagging in three short axis
slices. Figure 1 Flow chart demonstrating study plan.
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The epicardium and endocardium will be contoured on
the perfusion images, along with a region of interest in the
LV blood pool, to generate signal intensity curves. The
arterial input function corrected for signal saturation will
be used for myocardial blood ﬂow (MBF) quantiﬁcation
by model-independent deconvolution.
38 Transmural MPR
will be calculated by dividing hyperaemic blood ﬂow by
resting blood ﬂow. Ten patients will undergo repeat adeno-
sine stress CMR (within 10 days) to assess the reproducibil-
ity (coefﬁcient of variation) of MPR in AS. Focal and
diffuse ﬁbrosis will be assessed using LGE and precontrast
and postcontrast T1 mapping to estimate the myocardial
ECV.
39 Tagging will be analysed using InTag postproces-
sing toolbox (Creatis, Lyon, France) in OsiriX (Geneva,
Switzerland).
At the 12-month visit, with additional consent, the rate
of change in MPR will be assessed in those patients who
have not developed symptoms. This will allow correlation
of MPR with LV remodelling, diffuse and focal LV ﬁbro-
sis development. All CMR scans will be analysed at the
core lab (University of Leicester) by a single investigator
blinded to all patient details.
CT coronary artery calcium scoring
The role of subclinical coronary artery disease in the pro-
gression to symptoms in asymptomatic AS is unclear. CT
coronary artery calcium (CTCAC) scoring will be per-
formed on a multidetector CT scanner with ECG gating,
in a single breath-hold. Coronary artery calciﬁcation will
be reported as present/absent and scored according to
standard criteria to allow correlation of subclinical ath-
erosclerosis in relation to MPR. CT scans will be analysed
at the core lab in Leicester by a specialist cardiac radiolo-
gist. Reports will remain blinded except in the event of
potentially life-threatening incidental ﬁndings and
CTCAC >3 SDs above age-predicted values. The extent of
AV calciﬁcation will also be assessed in relation to valve
compliance and clinical outcome.
Follow-up
Patients will be followed up at 6 monthly intervals to a
maximum of 30 months. The research team will contact
patients by telephone just before the follow-up appoint-
ment is due, in order to optimise attendance, and travel
costs will be covered for their follow-up visits if required.
Each visit will include a history on development of any
typical symptoms, admissions to hospital, prespeciﬁed
MACE and venepuncture for NT-proBNP. For patients
who report typical symptoms or MACE, the responsible
clinician will be notiﬁed to consider referral for AVR.
The 12-month visit will take place at the tertiary cardiac
centres and if patients are asymptomatic, they will be
invited to have repeat CMR as per baseline.
Event adjudication
All patients will be registered with the National Health
Service (NHS) Information service or the Information
Services division in Scotland to verify outcomes and
acquire long-term data. Two independent cardiologists
will judge clinical events for the primary outcome.
Disagreement will be resolved by consensus and if neces-
sary by a third independent clinician.
Figure 2 MRI protocol used (4/2/3C, 4/2/3 chamber; LA, left atrial; LGE, late gadolinium enhancement; LV, left ventricular;
LVOT, left ventricular outflow tract).
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This will be performed under the supervision of IF at
the Robertson Centre for Biostatistics. All patients
recruited will have a minimum of 1 year of follow-up for
the primary outcome. The relationship between MPR
and exercise testing with 1-year outcome will be analysed
using logistic regression. The MPR cut-point for predict-
ing the primary outcome will be determined from
receiver operating characteristic analysis and will be
selected to match the sensitivity of exercise-induced
symptoms. Paired comparisons of the speciﬁcities of the
two approaches on the same dataset will be carried out
using McNemar’s test. The prognostic value of exercise
test symptoms at low workload and MPR individually and
in combination will be assessed for the full follow-up
period using Cox-regression analyses, testing the signiﬁ-
cance of MPR in the presence of exercise test data,
NT-proBNP and by calculating and comparing c-statistics
(discrimination), Hosmer Lemeshow statistics (calibra-
tion) and net reclassiﬁcation indices (prognostic value).
Predictors of MPR and VO2 will be assessed by univariate
and multivariate regression analysis. Time to event data
will be displayed using Kaplan-Meier curves and all
model assumptions will be assessed using appropriate
methods.
Power calculation
The study, with 170 participants will have 80% power
(binomial test) to show that MPR has superior overall
accuracy (assumed 85%) in predicting symptom onset,
compared with the results of previous studies for exercise
testing (76%), assuming an annual event rate of 29%.
15
ETHICS AND DISSEMINATION
Ethics
The study will be conducted according to the principles
of the Medical Research Council Good Clinical Practice
guidelines, Declaration of Helsinki, Data Protection Act,
NHS Research Governance and relevant local and
national laws. All patients will provide written informed
consent during their ﬁrst visit, before any tests are
carried out, and will have had at least 24 h to decide
whether to participate or not prior to this.
Study organisation and oversight
The sponsor is the University Hospitals of Leicester NHS
Trust. A Trial Steering Committee (TSC) has been
appointed and is responsible for the scientiﬁc and
ethical conduct of the study. This consists of the inde-
pendent chairman and two members, the chief investi-
gator, two coinvestigators from the tertiary centres, a lay
representative, representative of the Clinical Trials and
Evaluation Unit and a representative of the sponsor. The
study protocol and subsequent amendments have been
approved by the TSC. A data monitoring committee was
deemed not necessary given the observational design.
Study timetable
Ethics application was approved in December 2011.
Study enrolment started in April 2012 and recruitment
is expected to be completed in November 2013 with a
further 12 months for follow-up, postprocessing and
close-out of the study. The main study paper will be sub-
mitted within 6 months of study close-out.
FUNDING SOURCES
The study has been funded by a grant from the National
Institute of Health Research (NIHR; Grant award
number: NIHR-PDF 2011-04-51 Gerald P McCann).
Additional support and resources for the study will be
provided by the NIHR Leicester Cardiovascular
Biomedical Research Unit and NIHR Comprehensive
Local Research Networks.
DISCUSSION
Limitations
The primary endpoint includes AVR for symptom develop-
ment, which is subjective in nature. However, AVR by itself
is deliberately not considered an endpoint due to the vari-
ability in clinical practice in referring severe but asymp-
tomatic patients for surgery. Such patients will also be
excluded from primary endpoint analysis. The presence of
underlying coronary artery disease (CAD) may affect MPR
and possibly symptom development. Although previous
coronary artery bypass grafting/myocardial infraction with
6 months is an exclusion criteria, the patients will not
undergo coronary angiography to exclude CAD. The pos-
sibility of CTcoronary angiography was considered but the
high radiation dose at the time of study planning, adminis-
tration of intravenous contrast and β-blockers, was not felt
to be justiﬁed in asymptomatic patients.
Anticipated health benefits
The study will address a number of limitations in previ-
ously published data, with the primary endpoint being
driven by symptom development and MACE. The study
should identify the strongest prognostic markers on
which to base identiﬁcation of asymptomatic patients
with moderate-to-severe AS for consideration of early
(before symptoms develop) AVR. The efﬁcacy of such a
strategy should be assessed in a prospective randomised
controlled trial of early surgery in those with impaired
MPR versus watchful waiting until symptom development.
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